Could Celgene Shake Up the CAR-T Market? – Motley Fool
Motley Fool |
Could Celgene Shake Up the CAR–T Market?
Motley Fool The current CAR-T party of two might have a couple of new companions on the way. And those new entrants could bring some excitement to the party. Only two chimeric antigen T–cell receptor (CAR-T) therapies are currently approved by the FDA — Novartis' … Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst bluebird shares recover after slump following ASCO CAR–T data presentation Celgene (CELG), bluebird bio (BLUE) Phase I Study of bb2121 Demonstrates Deep and Durable Responses at ASCO |
